These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 1659287)
1. Effects of Ro 24-4736 in antagonizing the platelet and bronchoconstrictor responses to PAF. O'Donnell M Ann N Y Acad Sci; 1991; 629():416-8. PubMed ID: 1659287 [No Abstract] [Full Text] [Related]
3. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029 [TBL] [Abstract][Full Text] [Related]
4. MK 287: a potent, specific, and orally active receptor antagonist of platelet-activating factor. Hwang SB; Lam MH; Szalkowski DM; MacIntyre DE; Bach TJ; Luell S; Meuer R; Sahoo SP; Alberts AW; Chabala JC J Lipid Mediat; 1993 Jun; 7(2):115-34. PubMed ID: 8400114 [TBL] [Abstract][Full Text] [Related]
5. [Effect of analogs and antagonists of the thrombocyte-activating factor (PAF) on blood platelet aggregation]. Lakin KM; Kulikov VI; Manevich EM; Muliar AG; Shvets VI Farmakol Toksikol; 1988; 51(4):113-23. PubMed ID: 2847936 [No Abstract] [Full Text] [Related]
6. The benzodiazepine receptor ligands RO 5-4864 and RO 15-1788 do not block the inhibition of PAF-induced platelet aggregation seen with the hetrazepine WEB2086. Griffin K; Hong T; Levy JV Biochem Biophys Res Commun; 1989 Apr; 160(1):263-7. PubMed ID: 2540748 [TBL] [Abstract][Full Text] [Related]
7. A specific, photolabile and irreversible antagonist (L662,025) of the PAF-receptor. Hussaini IM; Shen TY Biochem Biophys Res Commun; 1989 May; 161(1):23-30. PubMed ID: 2543410 [TBL] [Abstract][Full Text] [Related]
8. Competitive inhibition of tritium-labeled platelet-activating factor binding to rabbit platelet membranes by amiloride and amiloride analogs. Hwang SB Biochem Biophys Res Commun; 1989 Aug; 163(1):165-71. PubMed ID: 2549986 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes; studies with yangambin. Herbert JM; Castro-Faria-Neto HC; Barbosa-Filho JM; Cordeiro RS; Tibiriça E J Lipid Mediat Cell Signal; 1997 Sep; 17(1):1-14. PubMed ID: 9302650 [TBL] [Abstract][Full Text] [Related]
10. Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells. Korth R; Hirafuji M; Keraly CL; Delautier D; Bidault J; Benveniste J Br J Pharmacol; 1989 Oct; 98(2):653-61. PubMed ID: 2555017 [TBL] [Abstract][Full Text] [Related]
11. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist. Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114 [TBL] [Abstract][Full Text] [Related]
12. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Tsunoda H; Sakuma Y; Harada K; Muramoto K; Katayama S; Horie T; Shimomura N; Clark R; Miyazawa S; Okano K Arzneimittelforschung; 1990 Nov; 40(11):1201-5. PubMed ID: 2085331 [TBL] [Abstract][Full Text] [Related]
13. Ex vivo effects of SR 27417, a novel PAF antagonist, on rabbit platelet aggregation and [3H]-PAF binding. Herbert JM; Laplace MC; Maffrand JP J Lipid Mediat; 1992 Feb; 5(1):1-12. PubMed ID: 1327264 [TBL] [Abstract][Full Text] [Related]
14. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action. Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772 [TBL] [Abstract][Full Text] [Related]
15. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets. Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712 [TBL] [Abstract][Full Text] [Related]
16. Propenyl carboxamide derivatives as antagonists of platelet activating factor. Guthrie RW; Kaplan GL; Mennona FA; Tilley JW; Kierstead RW; O'Donnell M; Crowley H; Yaremko B; Welton AF J Med Chem; 1990 Oct; 33(10):2856-64. PubMed ID: 2170651 [TBL] [Abstract][Full Text] [Related]
17. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation. Tahraoui L; Floch A; Mondot S; Cavero I Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653 [TBL] [Abstract][Full Text] [Related]
19. Studies of the combination of Ro 24-5913, a peptidoleukotriene antagonist, and Ro 24-4736, a PAF antagonist, in guinea pig and rat models of lung inflammation. Welton AF; O'Donnell M; Renzetti L; Simko B; Tocker J; Cashin C; Newbold P; Wasserman MA Ann N Y Acad Sci; 1994 Nov; 744():274-88. PubMed ID: 7825850 [No Abstract] [Full Text] [Related]
20. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies. Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]